Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO.
VA St. Louis Health Care System, St. Louis, MO.
Ann Surg. 2023 Apr 1;277(4):e933-e940. doi: 10.1097/SLA.0000000000005312. Epub 2021 Nov 18.
To define the relationship between the duration of smoking cessation and postoperative complications for patients with lung cancer undergoing surgical treatment.
Smoking increases the risk of postoperative morbidity and mortality in patients with lung cancer undergoing surgical treatment. Although smoking cessation before surgery can mitigate these risks, the ideal duration of preoperative smoking cessation remains unclear.
Using a uniquely compiled Veterans Health Administration dataset, we performed a retrospective cohort study of patients with clinical stage I non-small cell lung cancer undergoing surgical treatment between 2006 and 2016. We characterized the relationship between duration of preoperative smoking cessation and risk of postoperative complications or mortality within 30-days using multivariable restricted cubic spline functions.
The study included a total of 9509 patients, of whom 6168 (64.9%) were smoking at the time of lung cancer diagnosis. Among them, only 662 (10.7%) patients stopped smoking prior to surgery. Longer duration between smoking cessation and surgery was associated with lower odds of major complication or mortality (adjusted odds ratio [aOR] for every additional week, 0.919; 95% confidence interval [CI], 0.850-0.993; P = 0.03). Compared to nonsmokers, patients who quit at least 3 weeks before surgery had similar odds of death or major complication (aOR, 1.005; 95% CI, 0.702-1.437; P = 0.98) whereas those who quit within 3 weeks of surgery had significantly higher odds of death or major complication (aOR, 1.698; 95% CI, 1.203-2.396; P = 0.003).
Smoking cessation at least 3 weeks prior to the surgical treatment of lung cancer is associated with reduced morbidity and mortality. Providers should aggressively encourage smoking cessation in the preoperative period, since it can disproportionately impact outcomes in early-stage lung cancer.
明确肺癌手术患者戒烟持续时间与术后并发症之间的关系。
吸烟会增加肺癌手术患者术后发病率和死亡率。尽管术前戒烟可以降低这些风险,但术前戒烟的理想持续时间尚不清楚。
利用退伍军人事务部(Veterans Health Administration)独特的数据集,我们对 2006 年至 2016 年间接受手术治疗的临床 I 期非小细胞肺癌患者进行了回顾性队列研究。我们使用多变量限制立方样条函数,分析了术前戒烟持续时间与术后 30 天内并发症或死亡率风险之间的关系。
该研究共纳入 9509 例患者,其中 6168 例(64.9%)在诊断为肺癌时正在吸烟。其中,仅有 662 例(10.7%)患者在手术前戒烟。戒烟与手术之间的时间间隔越长,发生重大并发症或死亡的可能性越低(每额外一周的调整后比值比[aOR]为 0.919;95%置信区间[CI],0.850-0.993;P=0.03)。与不吸烟者相比,至少在手术前 3 周戒烟的患者死亡或发生重大并发症的可能性相似(aOR,1.005;95%CI,0.702-1.437;P=0.98),而在手术前 3 周内戒烟的患者死亡或发生重大并发症的可能性显著更高(aOR,1.698;95%CI,1.203-2.396;P=0.003)。
在肺癌手术治疗前至少戒烟 3 周与降低发病率和死亡率相关。医务人员应在术前积极鼓励患者戒烟,因为这可以显著改善早期肺癌患者的结局。